PEDIATRIC LIVER TRANSPLANT FOR METABOLIC...

PEDIATRIC LIVER TRANSPLANT FOR METABOLIC DISEASE

Rakesh Sindhi, MD.

George Mazariegos, MD

Hillman Center for Pediatric Transplantation Children’s Hospital of Pittsburgh, Pittsburgh, PA.

Greetings from the Children’s Hospital of Pittsburgh

Objectives Discuss the current state

of pediatric liver transplant Review indications and

outcomes for Tx in IEM Compare decision making TX for cure: MSUD Tx for treatment: MMA, PA

Surgical Considerations Areas of focus and

progress in liver transplant Long term outcomes Investigating Tolerance

• OPTN DATA – January 2011 through May 31, 2013

4

113 123 121 129 101

129 111

70 49 65 60

73

60 63

0

20

40

60

80

100

120

140

160

180

200

2006 2007 2008 2009 2010 2011 2012*

PedsAdult

Liver Transplants for Metabolic Disease by Year by Pediatric & Adults

UNOS

Objectives Discuss the current state

of pediatric liver transplant Review indications and

outcomes for Tx in IEM Compare decision making TX for cure: MSUD Tx for treatment: MMA, PA

Surgical Considerations Areas of focus and

progress in liver transplant Long term outcomes Investigating Tolerance

When do we transplant?: Metabolic disease

Structural liver disease Tumor Risk Extrahepatic manifestations: Neurologic Systemic (Cardiac, renal, etc) Quality of Life How do we time transplant to optimize these outcomes?

Metabolic conditions with liver injury METABOLIC DEFECT MAINLY

EXPRESSED IN THE LIVER

• Alpha-1-antitrypsin deficiency (PiZ) • Tyrosinaemia type I • BSEP deficiency • MDR-3 deficiency • Primary bile acid synthesis disorders • Hepatic porphyrias

– Acute intermittent porphyria – Variegate porphyria

• Glycogen storage disease type Ia • Hereditary fructose intolerance • Indian childhood cirrhosis • Mucopolysaccharidoses

METABOLIC DEFECT EXPRESSED IN OTHER ORGANS OR TISSUES • Wilson disease • Cystic fibrosis • FIC-1 deficiency • Glycogen storage disease types Ib, III

and IV • Non-alcoholic steatohepatitis • Lysosomal storage diseases • Gaucher disease • Niemann-Pick disease • Cholesterol ester storage disease • Mitochondrial cytopathies • Cerebrotendinous xanthomatosis • Cytrin deficiency • Congenital disorders of glycollisation

(CGD) • Galactosemia • Erythropoietic porphyria

From Molecular Genetics and Metabolism 111(2014):418-427

Metabolic conditions with no liver injury

METABOLIC DEFECT MAINLY EXPRESSED IN THE LIVER

• Crigler-Najjar syndrome type 1 • Primary hyperoxaluria • Urea cycle disorders • Familial hypercholesterolemia • Fatty acid oxydation defects • Coagulation defects

– Haemophilia A – Factor V and VII deficiency – Protein C and S deficiencies

• Factor H deficiency • Afibrinogenaemia • Amyloidosis type 1

METABOLIC DEFECT EXPRESSED IN OTHER ORGANS OR TISSUES

• Citrulinaemia • Cystinosis • Branched amino acids disorders

(organic acidemias) – Propionic acidemia – Methyl malonic acidemia – Mevulonic acidemia – Maple syrup urine disease

From Molecular Genetics and Metabolism 111(2014):418-427

RISKS AND BENEFITS

Medical management Natural history - phenotype Frequency/severity of decompensations Risks of end organ damage Quality of life/adherence Mortality

Liver transplant Local organ availability

Surgical complications

Early mortality

Degree of metabolic correction

Life long immunosupression

Adherence

Courtesy, D. Hadzic

OUTCOMES: UNOS Pediatric patient and graft survival

Goh A; Terasaki Foundation Laboratory, Los Angeles, CA, USA. Clin Transpl. 2008:19-34; An analysis of liver transplant survival rates from the UNOS registry.

OUTCOMES: metabolic disease vs. chronic liver disease

UNOS, Kayler, 2003

N %

Metabolic disease (N = 446) Urea cycle defects 114 25.6 Alpha 1 antitrypsin deficiency 88 19.7 Cystic fibrosis 48 10.8 Wilson disease 34 7.6 Maple syrup urine disease 29 6.5 Tyrosinemia 33 7.4 Glycogen storage disease 23 5.2 Crigler-Najjar 21 4.7 Neonatal hemochromatosis 18 4.0 Primary hyperoxaluria 9 2.0 Inborn error in bile acid metabolism 3 0.7

Other metabolic disease 26 5.8

Non-metabolic disease (N = 2551) Biliary atresia 1214 47.6 Fulminant liver failure 421 16.5 Other cholestatic 386 15.1 Tumor 212 8.3 Other 318 12.5

Metabolic and non-metabolic liver diseases as primary diagnosis, SPLIT registry

SPLIT

SPLIT, Arnon, 2010

Patient Survival Graft Survival

Pediatric LTx, Metabolic and Non-metabolic liver disease

Causes of death in patients treated with LT

Cause of death Metabolic liver disease Number (%)

Non-metabolic liver disease Number (%)

Total 37 (100.0%) 302 (100.0%)

Multi-organ failure 10 (27.0) 40 (13.2)

Cardiopulmonary 11 (29.7) 32 (10.6)

Cerebral edema 0 (0) 21 (7.0)

Sepsis 4 (10.8) 24 (7.9)

Primary non-function 3 (8.1) 13 (4.3)

Bacterial infection 0 (0) 21 (7.0)

Lymphoproliferative disease

2 (5.4) 10 (3.3)

Hepatic artery thrombosis

3 (8.1) 8 (2.6)

Other 4 (8.1) 133 (44.0) SPLIT

Metabolic disease, liver transplant (CHP 1981-2011, n=285)

A1AT, 25.6

MSUD, 13.3

Familial Cholestasis, 13

Wilson, 9.80

Tyrosinemia, 7

CF, 6.7

GSD, 5.3

CNS, 5.3 Urea cycle, 4.9

Oxalosis, 3.5 Other, 5.6

Disease Indications (%)

A1AT

MSUD

Familial Cholestasis

Wilson

Tyrosinemia

CF

GSD

CNS

Urea cycle

Oxalosis

0 5 10 15 20 25 30 Years

2000s

1980s

1990s

CHP

Objectives Discuss the current state

of pediatric liver transplant Review indications and

outcomes for Tx in IEM Compare decision making TX for cure: MSUD Tx for treatment: MMA, PA

Surgical Considerations Areas of focus and

progress in liver transplant Long term outcomes Investigating Tolerance

MAPLE SYRUP URINE DISEASE

35 patients + 17 from UNOS

Liver expresses 9-13% of total body branched chain ketoacid dehydrogenase complex activity

Indications Severe “classical” MSUD Age at Tx 9.9 years (1.7-32.1y) Graft type Cadaveric Domino transplant in 6 cases (all alive & well) Survival 100% patient and graft survival (median f/u 4.5y) 17 UNOS cases 1 death, 1 Re Tx, 1 LRLT

Mazariegos et al, 2012

MAPLE SYRUP URINE DISEASE

Mazariegos et al, 2012

METABOLIC CONTROL

Plasma leucine

Leucine/isoleucine Leucine/valine

35 cases

MAPLE SYRUP URINE DISEASE Neurological outcomes: IQ and adaptive score pre and 1 year post

Tx (n=14)

Mazariegos et al, 2012

MSUD Perioperative and Post-Operative Complications in 37 Patients

Post –Surgical Interventions Number Percent

Delayed wound closure 10 27

Ventral hernia repair 4 11

Gastrocutaneous fistula closurea 2 5

Exploratory laparotomy

• hepatic artery thrombosis with successful revision 2 5

• hepatic artery revision or graft revision 3 8

• intra-abdominal bleeding 1 3

• partial small bowel obstruction 1 3

Pleurocentesis 2 5

Chest tube drainage 2 5

Bronchoscopy 1 3

Medical Complications

• Acute rejectionb 15 40

• EBV disease 2 5

• CMV disease 1 3

• Post-transplant lymphoproliferative diseasec 1 3

a At prior gastrostomy tube sites bAntibody therapy for steroid-resistant rejection in 3/15 (8% of all patients) cIntestinal PTLD developed in one patient transplanted at another center; it resolved with transient withdrawal of immunosuppression and she has been disease-free for 12 years.

Cohort N Patient survival (%) p-value* 1 year 5 years 10 years

Peds<21 76 98.6 98.6 NA 0.673 Adults>=21 13 99.9 99.9 NA *p-value of log rank test of equality of survival distributions b/w age groups

Patient survival ped & adult LTx MSUD

PROPIONIC ACIDEMIA

26 cases Indications neonatal onset poor metabolic control Age at Tx 7m-9y median 2y Graft type LRLT 8 (30%) APOLT 1 Re-Tx 3 (11%) Survival 19 (73%) 6 deaths at <1 year post Tx follow up: 7m-15y

Barshes et al, 2006, Manzoni et al, 2006, Sato et al, 2009, Gissen et al, 2001, Vara et al, 2011, Kasahara et al, 2011

PROPIONIC ACIDEMIA

19 survivors Metabolic control • 2 children further decompensation • 1 metabolic stroke • 50-60% reduction in serum metabolites • Persistence of propionyl-carnitine and methyl-citrate

in urine

Barshes et al, 2006, Manzoni et al, 2006, Sato et al, 2009, Gissen et al, 2001, Vara et al, 2011, Kasahara et al, 2011

PROPIONIC ACIDEMIA

19 survivors Growth improved, some better feeding Diet Normal - variable protein restriction +/- L carnitine Neurodevelopment Decline halted (one metabolic stroke; MRI) Immunity 2 PTLD/CMV/HSV Renal function no documented major changes Cardiomyopathy reversed after Tx Romano et al, 2010

Barshes et al, 2006, Manzoni et al, 2006, Sato et al, 2009, Gissen et al, 2001, Vara et al, 2011, Kasahara et al, 2011

PA – King’s experience

5 pts • 4 neonatal presentation, 1 antenatal dg • Main LT indication: metabolic instability • All had some neurodevelopmental delay • Median age at tx: 1.5 yrs (0.8-7) • 1 re-Tx (HAT) • PTLD (1), recurrent HS (1) • All a/w after median 7.3 yrs (2.2-15)

Courtesy, D Hadzic

Cohort N Patient survival (%) 1 year 5 years 10 years

Peds<21 24 76.5 76.5 NA

Patient survival pediatric LTx: Other Organic Aciduria (PA)

METHYL-MALONIC ACIDEMIA

22 survivors

KT (n=6) 2 died sepsis 1 diabetes 1 acidosis 1 chronic rejection LT (n=15) 2 died infection, 1 acidosis 4 progressive renal failure 3 neurological disorder (one late stroke) 3 infection - bronchiolitis/CMV/EBV 1 acidosis CLKT (n=6) 1 infection - CMV 2 neurological disorder

Kasahara et al, 2006, McGuire et al 2008

METHYL-MALONIC ACIDEMIA

22 survivors Metabolic control • 3 episodes of acidosis/decompensation (1 death)

• Serum MMA decreased to 13.8% of pre-op values in LT pts -

better in CLKT pts

• Protein restriction 1g/kg/d to 2/g/kg/d in LT group

Kasahara et al, 2006, McGuire et al 2008

• Developed in context of enbloc liver intestinal transplantation and as a technical solution to lack of abdominal venous access in renal recipients

• En bloc Liver/kidney (n=4) – MMA -3 – Congenital hepatic

fibrosis/ARPCKD -1

• En Bloc liver/intestine/kidney (n=6)

CHP Liver Kidney En Bloc Technique

32

Lt FOR MMA - Conclusions

LT does not cure the disease -May decrease the disease activity

-May improve quality of life

Early LT might be recommended to reduce the magnitude of progressive neurological disability

Combined L-K is an effective treatment modality in patients with MMA and renal failure

Progressive renal and neurological deterioration post-LT may not be prevented

Cohort N Patient survival (%) p-value* 1 year 5 years 10 years

Peds<21 32 93.4 93.4 93.4 0.654 Adults>=21 3 99.9 NA NA *p-value of log rank test of equality of survival distributions b/w age groups

Patient survival pediatric & adult LTx: MMA

Objectives Discuss the current state

of pediatric liver transplant Review indications and

outcomes for Tx in IEM Compare decision making TX for cure: MSUD Tx for treatment: MMA, PA

Surgical considerations Areas of focus and

progress in liver transplant Long term outcomes Investigating Tolerance

How to perform transplant in metabolic conditions ?

• Technical aspects; size, age • Choosing graft type

– Impact of local donor availability – Understanding specific disease to estimate

sufficient enzyme activity required – Assessing impact of heterozygous

phenotype + stress

Courtesy D. Hadzic

Graft type in pediatric liver transplant

Copyright ©2008 American Academy of Pediatrics

Ng, V. L. et al. Pediatrics 2008;122:e1128-e1135

Kaplan-Meier probability of first allograft survival by graft type among 5-year survivors of pediatric LT

Auxiliary liver transplantation

• Metabolic liver-based conditions – C-N type 1 – Organic acidemias – Urea cycle disorders – Coagulation factor deficiencies

• Acute liver failure (non-A-E) – Living-related option – Prospects of IS withdrawal

Courtesy D. Hadzic

What about living donors?

Indications for living donor liver tx in IEM (Morioka, 2007)

LRLT In MMA and PA MMA (Morioka et al): 7 pediatric patients (7 months-7.5 yrs) Follow up 4-21 months, median 10.5 months 6/7 patient survival ? Assessing need for simultaneous Renal Tx

PA (Kasahara et al, 2012): 3 patients, 3/3 survivors Recommendation for early TX in neonatal

onset PA

Morioka et al. AJT 2007:7:2782-2787 Kasahara et al. Pediat Transplant 2012: 16:230-234

LRLTx for metabolic disease (Kasahara, 2014, 10-year patient survival 82% )

• Feier et al Hospital Sirion-Libanes, Sao Paulo Brasil – 2 yo child with MSUD – Maternal donor – DNA analysis post

transplantation

Living related liver transplantation in MSUD

44

MSUD: Domino Transplant

7 domino transplants

Recipients 6.97 – 64.59 (Y)

HCV, PSC, PFIC, CF, CHF, PBC, EC

F/U 12.06 – 72.12 (M)

9%

9%

82%

Relative Contribution of Various Organs to Whole Body Leucine Degradation

LiverBrainOther

Less invasive transplant options? Hepatocyte transplantation

Objectives Discuss the current state

of pediatric liver transplant Review indications and

outcomes for Tx in IEM Compare decision making TX for cure: MSUD Tx for treatment: MMA, PA

Surgical considerations Areas of focus and

progress in liver transplant Long term outcomes Investigating Tolerance

Etiology of late mortality and graft loss (Soltys et al, 2007)

EVIDENCE OF OVER IMMUNOSUPPRESSION (INFECTION) AS WELL AS UNDER IMMUNOSUPPRESSION (IMMUNE INJURY)

Extra-Hepatic Morbidity at the 10-Year Anniversary Clinic Visit

% o

f pat

ient

s

cGFR < 90 PTLD BMI choles triglyceride

0

5

10

15

20

25

30

35

40

SPLIT

Contributors to late allograft dysfunction

Technical

Immune

Infection

Recurrent disease

Ischemia (non-

technical)

Non- adherence

Monotherapy FK Dosing of liver transplanted MSUD patients with 3 year follow-up

Once Daily, 5, 20%

Twice daily, 12, 48%

One time / week, 1, 4%

Two times a/week, 2, 8%

Five times / week , 2, 8%

Six times /week, 3,

12%

Need for improved immune monitoring

Rejection risk assessment Measuring antiviral (CMV) immunity

JAMA 307:283-293, 2012

Closing thoughts and acknowledgements

Liver transplant for Metabolic Disease Complex, individualized decision making Optimal results require multidisciplinary,

comprehensive care with a long term view We must aim for the “ideal” survivor

Acknowledgements SPLIT ( Ronan Arnon) King’s College UK ( Dino Hadzic) Clinic for Special Children (Kevin Strauss and

Holmes Morton)

“We don’t have the luxury of choosing what we need to study… The problems that drive us in our research are the problems that our patients face every day” Kevin Strauss

“Children are the trailblazers”...Dr Starzl

- National Geograp National Geographic Traveler National Geographic Traveler hic Traveler

Thank you.